Drug intelligence / Profile preview

131I 1H10 F(ab')2

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

131I 1H10 F(ab')2 is a radioimmunotherapeutic and diagnostic agent consisting of the F(ab')2 fragment of the murine IgG3 monoclonal antibody 1H10, radiolabeled with the radioisotope iodine-131 (131I). The 1H10 antibody specifically recognizes a 48-55 kDa tumor-associated antigen expressed on the surface of human cervical carcinoma cells, including the CaSki cell line. The use of the F(ab')2 fragment instead of the full IgG molecule is intended to improve tumor penetration and accelerate blood clearance, thereby reducing systemic toxicity. In preclinical studies, the agent has demonstrated specific localization in solid cervical tumor xenografts and significant suppression of tumor growth through the delivery of cytotoxic beta-radiation, while also allowing for radioimmunoscintigraphic imaging.

Other names
[131I]1H10 F(ab')2131I-labeled 1H10 F(ab')2iodine I 131 1H10 F(ab')2
02

Targets

MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on 131I 1H10 F(ab')2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 131I 1H10 F(ab')2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call